In this review, we discuss known data and the differences between the different immune checkpoint inhibitors, as well as future avenues to explore with immuno-oncologic agents in urothelial cancer.
Amishi Y. Shah, MD
Advertisement
Articles by Amishi Y. Shah, MD
Advertisement
Latest Updated Articles
Current and Future Landscape of Immune Checkpoint Inhibitors in Urothelial CancerPublished: January 17th 2019 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
AI-Powered Scout Platform Could Enhance Oncology Decision-Making With Data- and Expert-Driven Insights
2
Molecular Insights Into Cancer Cachexia: An Evolution in Identifying the Syndrome
3
FDA Grants Interchangeability Designation to 2 Denosumab Biosimilars
4
Sac-TMT Combo Produces Encouraging Activity in Pretreated Metastatic CRPC
5
